Invitrogen™ Icatolimab Recombinant Monoclonal Antibody

Description

For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.

Icatolimab, also known as JS004 or TAB004, is a humanized IgG4 monoclonal antibody with a hinge mutation (S228P) that targets B and T Lymphocyte Attenuator (BTLA) and inhibits its interaction with its ligand, Herpesvirus Entry Mediator (HVEM). BTLA (B and T lymphocyte attenuator), also known as CD272, is a member of the CD28 immunoglobulin-superfamily of co-inhibitory receptors. It is located on chromosome 3q13.2 in humans. Structurally, BTLA is characterized by an extracellular immunoglobulin-like variable domain and intracellular immunoreceptor tyrosine-based inhibition motifs (ITIMs). Functionally, BTLA is predominantly expressed on CD4+ and CD8+ T cells, B cells, and various other immune cells. It serves as a negative regulator of immune responses by transmitting inhibitory signals upon interaction with its ligand, HVEM (herpesvirus entry mediator). These interactions are crucial in maintaining immune homeostasis and preventing autoimmunity. BTLA expression decreases upon T cell activation and is implicated in various immune disorders and cancer, where it modulates immune evasion mechanisms.